MKI67 and metastatic malignant neoplasm in the lymph nodes: Compared with non-carriers, PALB2 carriers exhibited a slightly higher Ki-67 index (83.3% vs. 74.9%, p = 0.741), larger tumor size (66.7% vs. 53.4%, p = 0.4), and lymph node metastasis (75.0% vs. 50.9%, p = 0.146).